Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems

Wancheng Guo, Yihao Zhan, David E. Mery, Eric R. Siegel, Fumou Sun, Yan Cheng, Cody Ashby, Zijun Zhang, Clyde Bailey, Daisy Alapat, Hongling Peng, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D. Shaughnessy, Fenghuang ZhanBlood 2024 · DOI · OpenAlex

Introduction

Multiple Myeloma (MM) is characterized by significant clinical and biological heterogeneity. While established staging systems like the International Staging System (ISS) and its revised versions (R-ISS and R2-ISS) utilize markers such as Beta-2-microglobulin (B2M), albumin, lactate dehydrogenase (LDH), and cytogenetic abnormalities, a subset of high-risk patients remains inadequately identified. This study, published in the Blood Cancer Journal, investigates the prognostic utility of serum ferritin—a common marker for iron stores—in MM patients undergoing Autologous Stem Cell Transplantation (ASCT).

Methodology

The researchers performed a retrospective analysis of 3,446 consecutive MM patients treated at the University of Arkansas for Medical Sciences (UAMS) between 1983 and 2019. High ferritin levels were defined as $\ge 336$ mg/L for males and $\ge 306$ mg/L for females. The study employed multivariable Cox regression models to assess the independent prognostic value of ferritin after adjusting for age, gender, race, and standard clinical markers. Furthermore, the researchers integrated ferritin data with four Gene Expression Profiling (GEP) models (GEP70, GEP80, PI, and Sky92) and the ISS/R-ISS/R2-ISS staging systems to evaluate improvements in predictive accuracy.

Results and Clinical Significance

The analysis revealed that high serum ferritin is a robust and independent predictor of poor outcomes. In a multivariable analysis of 1,688 patients, high ferritin was associated with a significantly increased risk for both Progression-Free Survival (PFS; HR: 1.67) and Overall Survival (OS; HR: 1.68).

Progression-free survival (PFS) stratified by ferritin levels across various patient subgroups, including overall cohort (A), gender (B), race (C), age (D), and treatment setting (E).

Key findings include:

  • Universality: The prognostic impact of ferritin was consistent across different ages, genders, and races, highlighting its versatility as a biomarker.
  • Independent Prognostic Value: Ferritin remained significant even when accounting for "gold standard" markers like B2M and chromosomal abnormalities. This suggests that ferritin captures unique biological signals, potentially related to the bone marrow microenvironment or systemic inflammation.
  • Refining Risk Stratification: High ferritin levels were able to identify high-risk biology even in patients classified as "low-risk" by genomic profiling (GEP). It also provided additional stratification for patients in ISS Stages II and III.
  • Validation: These findings were corroborated in a separate cohort of 708 non-transplant MM patients, suggesting that the prognostic value of ferritin is a general feature of the disease.

Discussion

Integrating serum ferritin—a simple, inexpensive, and widely available blood test—into existing MM staging models significantly enhances the identification of high-risk patients. While the exact mechanism remains to be fully elucidated (i.e., whether ferritin reflects iron overload or acts as an acute-phase reactant), its clinical utility is clear.

Limitations of the study include the small sample size in the highest-risk R2-ISS Stage IV group and the evolution of standard care over the multi-decade study period. Future research should explore the impact of modern quadruplet therapies and CAR-T cell treatments on the prognostic significance of ferritin.

Summary updated

BibTeX
@inproceedings{guo2024prognostic,
  author = {Wancheng Guo and Yihao Zhan and David E. Mery and Eric R. Siegel and Fumou Sun and Yan Cheng and Cody Ashby and Zijun Zhang and Clyde Bailey and Daisy Alapat and Hongling Peng and Samer Al Hadidi and Sharmilan Thanendrarajan and Carolina Schinke and Maurizio Zangari and Frits van Rhee and Guido Tricot and John D. Shaughnessy and Fenghuang Zhan},
  title = {{Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems}},
  booktitle = {Blood},
  year = {2024},
  doi = {10.1038/s41408-024-00998-9},
}
Figure